11.15CADMkt Cap: 31.01M CADP/E: —Last update: 2026-05-21
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap31.01M CAD
Enterprise Value29.87M CAD
Revenue (TTM)10.18M CAD
Gross Profit8.56M CAD
Net Income (TTM)-6.01M CAD
Revenue/Share3.890 CAD
Last Price11.15 CAD
Fiscal Year EndJul 2025
MR QuarterJan 2026
Employees8
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-7.31
EV/Revenue2.93
P/S3.05
P/B3.90
EPS (TTM)-3.47
EPS (Forward)—
52W Range
—
52W High11.15 CAD
52W Low11.15 CAD
Profitability
Gross Margin36.28%
Oper. Margin-460.48%
EBITDA Margin-40.11%
Profit Margin-25.49%
ROE-65.80%
ROA-37.98%
Growth
Revenue Growth-94.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.25M CAD
CapEx (TTM)17.35K CAD
FCF Margin-81.24%
FCF Yield-26.68%
Net Debt-1.13M CAD
Net Debt/EBITDA0.28
Balance Sheet
Debt/Equity0.01
Current Ratio1.56
Quick Ratio1.31
Book Value/Sh2.856 CAD
Cash/Share0.4650 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 19, 2017
Splits
Last Split1:60
Split DateJan 22, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.78M
Float2.43M
Insiders12.04%
Institutions0.00%
Short Interest
Short Ratio15.7d
Short % Out.0.01%
Shares Short17
Short (prev mo.)32
Technical
SMA 5011.35 (-1.8%)
SMA 20011.16 (-0.1%)
Beta1.49
S&P 52W Chg28.31%
Avg Vol (30d)0
Avg Vol (10d)260
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—